Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
446. |
ECCT/16/07/03 | CYP STUDY Primaquine metabolism and its association with CYP2D6 and CYP2C19 genotypes among adults living within Seme and Kisumu West sub-counties of Kisumu County, Western Kenya |
Principal Investigator(s) 1. BEN ANDAGALU 2. BEN ANDAGALU Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
View |
447. |
ECCT/21/02/02 | RESHAPE PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING BLEEDING INCIDENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS AND NON-INHIBITORS TREATED WITH EMICIZUMAB AND OTHER HEMOPHILIA TREATMENTS IN A REAL-LIFE SETTING |
Principal Investigator(s) 1. Festus Njuguna Site(s) in Kenya Moi Teaching and Referral Hospital |
View |
448. |
ECCT/14/09/02 | LIVING STUDY-PHASE III B. Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study) |
Principal Investigator(s) 1. Elizabeth Maleche Obimbo 2. Elizabeth Bukusi 3. Winstone Nyandiko 4. Bienvenu Baruani Ngoy 5. Joseph Kariuki Mbuthia 6. Allan Godfrey Otieno 7. Lucy Koech 8. Neema Mturi 9. Beatrice Mutai Site(s) in Kenya 1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county) 2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county) 3. MSF Belgium Kibera Clinic (Nairobi City county) 4. Gertrude\'s Children\'s Hospital (Nairobi City county) 5. Mbagathi District Hospital (Nairobi City county) |
View |
449. |
ECCT/08/27/12 | MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection. Protocol No. 110021 - MAL 55 STUDY A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa” |
Principal Investigator(s) 1. Dr. Mary Hamel 2. Dr. Patricia Njuguna 3. Dr. Walter Otieno Site(s) in Kenya 1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county) 2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county) 3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county) |
View |
450. |
ECCT/15/06/01 | Pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric uncomplicated falciparum malaria in Western Kenya |
Principal Investigator(s) 1. Patrick Sawa Site(s) in Kenya St. Judes Clinic, ICIPE |
View |